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2013, accepted Notrial ﬁbrillation (AF) has been found to occur with an increased frequency in patients withmalignancies, particularly in
those undergoing cancer surgery. The occurrence of AF in cancer may be related to comorbid states or a direct tumor
effect or may represent a complication of cancer surgical or medical therapy, whereas inﬂammationmay be a common
denominator for both conditions. Treating AF in patients with malignancies is a challenge, especially in terms of
antithrombotic therapy, because cancer may result in an increased risk of either thrombosis or hemorrhage and an
unpredictable anticoagulation response, whereas thromboembolic risk prediction scores such as CHADS2 (Cardiac
Failure, Hypertension, Age, Diabetes, and Stroke [doubled])may not be applicable. The general lack of evidence imposes
an individualized approach to themanagement of AF in those patients, although some general recommendations based
on current guidelines in noncancer patients and the existing evidence in cancer patients, where available, may be
outlined. (J Am Coll Cardiol 2014;63:945–53) ª 2014 by the American College of Cardiology FoundationAtrial ﬁbrillation (AF) is the most common sustained
arrhythmia; it affects 1.5% to 2% of the general population,
and this prevalence increases to 10% at 80 years of age and
to 18% at 85 years of age (1,2). In addition to aging, seve-
ral cardiovascular conditions, such as hypertension, heart
failure, and valvular disease, as well as noncardiovascular
conditions, such as chronic pulmonary disease, diabetes,
electrolyte abnormalities, thyroid dysfunction, and chronic
kidney disease, predispose to the development of AF (2).
Given the increasing occurrence of malignancies in the
elderly and the coexistence of other conditions predisposing
to AF in cancer patients, an association between those 2
conditions would be expected. On the other hand, AF
confers an increased risk of cardiovascular complications,
including a 5-fold risk of stroke and a 3-fold risk of heart
failure, as well as a doubled mortality rate (1). Therefore, AF
may present an additional factor affecting the prognosis
of malignant diseases and a challenge for the therapeutic
management of cancer patients.
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vember 19, 2013.exception of AF after cancer surgery (Table 1). A large
epidemiological study on 24,125 patients with newly diag-
nosed cancer recently shed some new light on the issue.
More speciﬁcally, the prevalence of AF at baseline (i.e., at
cancer diagnosis) was 2.4% (baseline AF), whereas AF
developed in another 1.8% of patients after the diagnosis of
cancer (new-onset AF) (3). In this study, new-onset AF was
associated with a 2-fold risk of thromboembolism and a 6-
fold risk of heart failure, even after adjustment for known
risk factors (adjusted hazard ratios [HRs]: 1.98 [p < 0.001]
and 6.3 [p < 0.001], respectively) (3).
The inverse approach was followed by another large
population-based cohort that compared the prevalence of
colorectal cancer in patients with and without AF. The
authors compared 28,333 patients with AF with 283,260
matched individuals without AF; the prevalence of colorectal
cancer was 0.59% in AF patients and only 0.05% in those
without AF (HR: 11.8) (4). Furthermore, in a cohort of
2,339 patients admitted for surgery, AF was present with
at least twice the frequency in patients admitted with a
ﬁrst diagnosis of colorectal or breast cancer than in those
admitted for nonneoplastic surgery (3.6% vs. 1.6%) (5). In
another study from the same group, patients with a ﬁrst
diagnosis of colorectal cancer had an approximately 3-fold
higher risk of AF compared with patients admitted for
nonneoplastic diseases (HR: 3.5) (6).
The most frequent form of cancer-related AF is that
occurring post-operatively (Table 1). AF is particularly
frequent during thoracic surgery, especially pulmonary
resection for lung cancer, an association that has been
reported since the early 1970s (7). In a large cohort of
13,906 patients who underwent lung cancer surgery, AF
occurred post-operatively in 12.6% of cases (8). Other
Table 1 Epidemiological E
First Author, Year (Ref. #)
Hu et al., 2012 (3)
Erichsen et al., 2012 (4)
Guzzetti et al., 2008 (5)
Guzzetti et al., 2002 (6)
Onaitis et al., 2010 (8)
Imperatori et al., 2012 (9)
Cardinale et al., 2007 (10)
Roselli et al., 2005 (11)
Nojiri et al., 2011 (13)
Salvatici et al., 2010 (14)
Cardinale et al., 1999 (15)
Nojiri et al., 2010 (16)
Nojiri et al., 2010 (50)
Ciszewski et al., 2013 (65)
Siu et al., 2005 (18)
Walsh et al., 2004 (24)
Ojima et al., 2013 (66)
Erichsen et al., 2011 (28)
Wilkinson et al., 2010 (29)
Arslan et al., 2011 (67)
Abonowara et al., 2012 (68)
AF ¼ atrial ﬁbrillation; TSH ¼ thyroid-stimu
Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CRP = C-reactive protein
HR = hazard ratio
LMWH = low molecular
weight heparin
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
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946studies in patients subjected to
lung cancer surgery reported
incidences ranging between 6%
and 32% (9–16), whereas a single
study on a small population re-
ported an incidence as high as
60% (17). Furthermore, post-
operative AF has been reported
in 4.4% of 563 patients who
underwent elective colectomy forcolorectal cancer (18), as well as in 9.2% of 207 patients who
underwent esophagectomy for esophageal cancer (19). Post-
operative AF seems to have a negative impact on patients’
prognosis. Thus, AF occurring during lung cancer surgery
increased post-operative mortality (6.7% vs. 1.0% in patients
without AF; p ¼ 0.024), hospital length of stay, and
intensive care unit admissions, and it was further associated
with an almost 4-fold higher long-term mortality in 5-year
survivors after adjustment for other risk factors (HR: 3.75;
p ¼ 0.007) (9). Whether there is a signiﬁcant difference
concerning post-operative AF in cancer patients compared
with noncancer patients undergoing similar surgical pro-
cedures is not easy to conclude on the basis of the available
evidence. A direct comparison is not available, whereas a
comparison on the basis of the results of different studies is
not possible given that AF prevalence is affected by and
therefore should be adjusted for several factors. A single large-
scale retrospective observational study involving 370,447
patients undergoing major noncardiac surgery reported a 3%
incidence of post-operative AF, with considerable variationvidence of AF in Patients With Cancer
No. of Patients Con
24,125 Various types of c
28,333 with AF and
28,3260 without AF
Colorectal cancer
1,317 Colorectal or brea
456 Colorectal cancer
13,906 Pulmonary resecti
454 Pulmonary resecti
400 Pulmonary resecti
604 Pulmonary resecti
553 Pulmonary resecti
400 Pulmonary resecti
233 Pulmonary resecti
126 Pulmonary resecti
80 Pulmonary resecti
117 Pulmonary resecti
563 Colectomy for colo
174 Colectomy for colo
207 Esophagectomy fo
11,887 Cancer  bisphos
20,571 Cancer  bisphos
124 Cancer þ bisphos
136 TSH suppression f
lating hormone.by race and type of surgery, but provided no data on the
impact of cancer surgery (19). On the other hand, post-
operative AF complicates w25% to 30% of patients un-
dergoing cardiac surgery such as coronary artery bypass
grafting or valve surgery (20,21). However, these latter
patients have established heart disease and undergo a pro-
cedure that involves direct manipulation of cardiac tissues,
and therefore AF occurrence is expected to be high (19).
The available evidence on the risk factors for the devel-
opment of post-operative AF in cancer patients is outlined
in Table 2.
In contrast to the aforementioned studies, there is
some evidence, derived by rather small study populations,
arguing against the association between AF and cancer or
the impact of AF on the prognosis of cancer patients (22).
Thus, cancer was not an independent predictor of atrial
arrhythmias in a cohort of 131 patients, whereas AF was not
an independent predictor of survival in 175 patients with
colorectal cancer (23,24). Sample size and the type and
severity of cancer in previous analyses represent important
factors that may account for the lack of data consistency.
Another essential issue is the methodology of AF detection
followed in different studies (i.e., symptoms driven, elec-
trocardiographic monitoring) that may have crucially affec-
ted the reported frequency.Pathophysiology
AF in cancer patients may represent a comorbid state
because those patients share several factors predisposing todition AF Prevalence
ancer 2.4% at cancer diagnosis plus
1.8% after cancer diagnosis (new onset)
Colorectal cancer: 0.59% in
AF vs. 0.05% in non-AF
st cancer 3.6%
5.2%
on for lung cancer 12.6%
on for lung cancer 9.9%
on for lung cancer 18%
on for lung cancer 19%
on for lung cancer 5.6%
on for lung cancer 18%
on for lung cancer 12%
on for lung cancer 23%
on for lung cancer 28%
on for lung cancer 16%
rectal cancer 4.4%
rectal cancer 5.4% (pre- and post-operatively)
r esophageal cancer 9.2%
phonates 3.2% in bisphosphonate group vs. 2.4% in controls
phonates 18.0% in bisphosphonate group vs. 12.7% in controls
phonate 0%
or thyroid cancer 10.3%
Table 2
Risk Factors for the Development of
Post-Operative Atrial Fibrillation in
Patients With Cancer
Demographic
Advanced age, male
Clinical
Advanced cancer stage, history of arterial hypertension, history of
paroxysmal atrial ﬁbrillation, physical status, post-operative tachycardia
Laboratory
Increased natriuretic peptides (NT-proBNP, BNP), ectopic beats on
electrocardiogram, mitral E/e0 ratio >8, low heart rate variability,
low mean heart rate
Treatment related
Increased duration of surgery, surgical complications, need for
post-operative blood transfusion, extended lung resection in lung cancer,
use of colon conduit in esophagectomy
Based on information from multiple studies (8–11,14,16,18,50,65,66).
BNP ¼ B-type natriuretic peptide; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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947AF such as advanced age, electrolyte abnormalities, hypo-
xia, and metabolic disorders (22,25,26). The autonomic
nervous system imbalance due to the increased sympathe-
tic drive caused by pain or other forms of physical or
emotional stress may also predispose to AF (27). AF may
further result from paraneoplastic conditions including hy-
perparathyroidism and autoimmune reactions against atrial
structures (27). AF may also represent a direct manifestation
of the neoplasm in the case of primary or metastatic cardiac
tumors or tumors of adjacent tissues such as the lungs andFigure 1 An Overview of the Potential Pathogenetic Mechanisms Lin
Cancer may cause atrial ﬁbrillation, rarely by direct invasion of the heart and more comm
autonomous nervous system (ANS) imbalance, paraneoplastic manifestation, and metab
conditions may predispose both to cancer and to atrial ﬁbrillation.esophagus that invade the heart. Moreover, AF may be a
complication of cancer therapy. As previously stated, post-
operative AF occurs frequently, particularly in the case of
pulmonary resection. In addition, several drugs used for the
treatment of cancer have been found to induceAF (22,28–32).
These drugs include most of the cytotoxic agents such as
cisplatin, 5-ﬂuorouracil, doxorubicin, paclitaxel/docetaxel,
ifosfamide, gemcitabine, and mitoxantrone; high-dose corti-
costeroids; antiemetic agents such as ondansetron; targeted
therapies; and bisphosphonates (22,28–33). A single study,
however, argued against biphosphonate related-AF (35).
Inﬂammation may be a common denominator of both
conditions. It has been suggested that AF may actually
represent an inﬂammatory complication of cancer (25). In a
population-based study in 5,806 subjects followed for a me-
dian of 7.8 years, C-reactive protein (CRP) increase
was associated both with the presence of AF at baseline (odds
ratio for fourth vs. ﬁrst CRP quartile: 1.8) and with future
AF development (HR for fourth vs. ﬁrst CRP quartile: 1.3)
(34). An increase in CRP and other inﬂammatory markers
such as tumor necrosis factor-a and interleukins 2, 6, and 8
has been found in AF (23,35), although an increased
neutrophil count was associated with the occurrence of
postoperative AF in patients who underwent surgery for
colorectal cancer (18).
Overall, the underlying mechanisms of AF induction in
cancer patients are poorly understood and remain to beking Cancer With Atrial Fibrillation
only by chemotherapy and supportive therapies, surgery, chronic inﬂammation,
olic, electrolyte, and other abnormalities. In addition, aging and coexisting comorbid
Table 3 Studies on the Prevention or Treatment of Post-Operative AF in Patients With Cancer
First Author, Year (Ref. #) No. Cancer Type Surgery Type Intervention Outcome
Prevention
Riber et al., 2012 (12) 254 Lung cancer Pulmonary resection Amiodarone AF reduction
(9% vs. 30%)
Nojiri et al., 2012 (17) 40 Lung cancer Pulmonary resection Atrial natriuretic peptide AF reduction
(10% vs. 60%)
Ciszewski et al., 2012 (60) 117 Lung cancer Pulmonary resection Acebutolol or diltiazem Nonsigniﬁcant AF reduction
(5% in acebutolol, 23% in
diltiazem, 20% in placebo)
Treatment
Nojiri et al., 2011 (13) 30 with AF Lung cancer Pulmonary resection Landiolol or verapamil
þ digoxin for cardioversion
Reduction of cardioversion time
(8 h vs. 11 h)
Ojima et al., 2013 (66) 19 with AF Esophageal
cancer
Transthoracic
esophagectomy
Medical cardioversion
(landiolol as ﬁrst-line therapy)
63.2% successful cardioversion
AF ¼ atrial ﬁbrillation.
Farmakis et al. JACC Vol. 63, No. 10, 2014
Atrial Fibrillation in Cancer March 18, 2014:945–53
948elucidated by future research. An overview of the potential
pathogenetic links between cancer and AF is outlined in
Figure 1.Treatment
Treatment of AF in cancer patients is a challenge, particu-
larly in terms of antithrombotic therapy for stroke preven-
tion. On the one hand, cancer is itself a prothrombotic
state, thus further increasing the risk of thromboembolic
events in patients with AF. Despite that, the history of
cancer has not been incorporated in the thromboembolic
risk prediction scores such as CHADS2 (Cardiac Failure,
Hypertension, Age, Diabetes, and Stroke [doubled]) or
CHA2DS2-VASc (congestive heart failure or left ventricu-
lar dysfunction, hypertension, age 75 [doubled], diabetes,
stroke [doubled]–vascular disease, age 65 to 74, sex [female])
that are currently suggested to be used to guide antith-
rombotic therapy (1,2). Moreover, some anticancer therapies
and in particular the novel angiogenesis inhibitors have been
related to thromboembolic complications (32). On the other
hand, some malignancies, such as primary or metastatic
intracranial tumors and hematological malignancies, pose
an increased risk of hemorrhage. To complicate thingsTable 4 Open Issues Concerning AF in Cancer Pa
Epidemiology Prevalence of AF in different types
Occurrence of AF in relation to var
Risk factors of AF
Impact of AF on cancer prognosis
Impact of AF on therapeutic decis
Pathogenesis Mechanisms of AF induction
Diagnosis and
assessment
Evaluation of classic and novel bio
Use of established thromboemboli
Evaluation of the need for cancer-
Management Evaluation of available strategies f
Use of novel anticoagulants for str
Use of available pharmacological t
Use of available pharmacological a
AF ¼ atrial ﬁbrillation; CHADS2 ¼ cardiac failure, Hypertension, Age, Diabetes
ventricular dysfunction, hypertension, age 75 (doubled), diabetes, stroke (dfurther, the response to anticoagulation may not be pre-
dictable owing to the concomitant medication or metabolic
disorders associated with cancer (36). Actually, the use of
vitamin K antagonists for deep venous thrombosis in pati-
ents with malignancies was associated with a 6-fold higher
risk of hemorrhage compared with patients without cancer
(37). In addition, there is practically no evidence to guide
practice, and the recent randomized clinical trials on the
novel anticoagulants dabigatran, rivaroxaban, and apixaban
for stroke prevention in AF did not include cancer patients
(38–40). Finally, using the established thromboembolic risk
prediction scores to guide antithrombotic therapy in cancer
patients may not be adequate. More speciﬁcally, in a large
cohort of 24,125 patients with newly diagnosed cancer,
although the CHADS2 score was predictive of thrombo-
embolism risk in patients with baseline AF, it did not pre-
dict thromboembolic events in those with new-onset AF
(i.e., AF that occurred after cancer diagnosis) (3). Therefore,
the decision regarding the initiation of antithrombotic
therapy in cancer patients has to be strictly individualized,
weighing cautiously the beneﬁts against the risks according
to the features of each particular patient.
Low molecular weight heparin (LMWH) may have a
more favorable outcome than vitamin K inhibitors intients
of cancer based on large cohorts or registries
ious cancer modalities, particularly novel targeted therapies
and outcome
ions concerning cancer management
markers for AF prediction
c risk assessment scores (i.e., CHADS2 or CHA2DS2-VASc)
speciﬁc scores
or stroke prevention
oke prevention (dabigatran, rivaroxaban, apixaban)
herapies and other strategies for AF prevention
nd interventional therapies for AF management
, and Stroke (doubled); CHA2DS2-VASc ¼ congestive heart failure or left
oubled)–vascular disease, age 65 to 74, sex (female).
Table 5
Practical Recommendations for the Screening and Management of Cancer-Related AF on the Basis of Current Guidelines
in Noncancer Patients and the Existing Evidence, Where Available, in Cancer Patients
Screening When
At cancer diagnosis
Perioperatively; strong evidence supports an increased occurrence, particularly in patients undergoing lung resection
Before and after chemotherapy and other cancer therapies; some evidence supports the association between AF and
cancer therapies, such as speciﬁc cytotoxic agents and supportive therapies such as bisphosphonates
At relative symptoms (persistent palpitations, irregular rhythm)
How
Pulse taking followed by electrocardiography
Prevention of thromboembolism When
At AF diagnosis, regardless of type (paroxysmal or persistent/permanent)
Estimation of TER
High TER in the presence of previous thromboembolism; moderate TER in the presence of age 75 years, hypertension,
heart failure or left ventricular ejection fraction 35%, and diabetes mellitus; validated TER assessment tools such as
CHAD2DS2-VASc score may be used
Consider antithrombotic therapy even in low TER patients (e.g., CHA2DS2-VASc score ¼ 0) given the additional TER associated
with certain cancers (e.g., pancreatic, ovarian, lung, primary hepatic) or cancer therapies (e.g., cisplatin, gemcitabine,
5-ﬂuorouracil, erythropoietin, granulocyte colony-stimulating factors)
Estimation of BR
Cancer-related high BR features such as intracranial tumor, hematological malignancies with coagulation defects, cancer
therapy–induced thrombocytopenia, and severe metastatic hepatic disease may be a contraindication to antithrombotic
therapy regardless of TER
Validated BR assessment tools such as HAS-BLED score may be used
Medication
Low molecular weight heparins: weak evidence suggests beneﬁcial effects in cancer patients
Vitamin K antagonists: consider interaction with concomitant cancer therapy
Aspirin: may be contraindicated because of thrombocytopenia
New oral anticoagulants: no data on cancer patients
Cardioversion Hemodynamically unstable patient
Electrical cardioversion
Hemodynamically stable patient
Perioperatively: weak evidence favors amiodarone and landiolol
Nonperioperatively: according to the presence and severity of structural heart disease; weak evidence favors ibutilide
Sinus rhythm maintenance medication Consider perioperative prophylaxis particularly in patients undergoing lung resection; weak evidence favors amiodarone
and landiolol
Consider in patients with recurrent paroxysmal episodes, advanced age, cardiovascular comorbidities, and so on
Consider potential interactions with concomitant cancer therapy
Rate control Main modality in end-stage metastatic disease on palliative care
No evidence for speciﬁc agents in cancer patients
Consider potential interactions with concomitant cancer therapy
Catheter ablation No evidence yet in cancer patients
May be a choice in patients with symptomatic paroxysmal atrial ﬁbrillation despite antiarrhythmic therapy
Consider patient’s preferences
Consider the presence of structural heart disease
Consider cancer prognosis (life expectancy)
Consider individual bleeding/thrombotic risks
Left atrial appendix closure/occlusion No evidence yet in cancer patients
May be a choice in patients with high TER and BR (see previous text)
Consider patient’s preferences
Consider cancer prognosis (life expectancy)
BR ¼ bleeding risk; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly;
TER ¼ thromboembolic risk; other abbreviations as in Table 4.
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949patients with malignancies. Actually, dalteparin was associ-
ated with better survival than coumarin derivatives in pa-
tients with nonmetastatic solid tumors and venous
thromboembolism (41). This may be related to the potential
antitumor and antimetastatic effects of LMWH that have
been shown to provide a survival beneﬁt in patients with
different types of cancer (42,43). As a result, the American
College of Chest Physicians recommended the use of
LMWH over vitamin K antagonists in cancer patients with
venous thromboembolism (44). The role of LMWH in
long-term anticoagulation therapy of patients with cancer
and AF remains to be proven.The decision regarding whether to begin antiarrhythmic
therapy may also be difﬁcult in cancer patients. In several
cases, restoration and maintenance of sinus rhythm are
necessary due to contraindications to long-term antith-
rombotic therapy. On the other hand, the antiarrhythmic
medications that are effective in rhythm control, such as
class III drugs, are associated with QT interval prolongation.
Prolongation of the QT interval may also result from several
drugs used in the treatment of cancer, including chemo-
therapeutic agents such as arsenic trioxide, targeted thera-
pies such as angiogenic inhibitors, and supportive therapies
such as ondansetron (45–47). Concomitant conditions such
Figure 2 Algorithm for Antithrombotic Therapy in Cancer-Related Atrial Fibrillation
A practical algorithm for antithrombotic therapy in cancer-related atrial ﬁbrillation. *Intracranial tumor, hematologic malignancies with coagulation defects, cancer therapy-
induced thrombocytopenia, severe metastatic hepatic disease etc. yHAS-BLED ¼ Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile
INR, Elderly, Drugs/alcohol concomitantly zCHA2DS2-VASc ¼ Congestive heart failure or left ventricular dysfunction Hypertension, Age  75 (doubled), Diabetes, Stroke
(doubled)-Vascular disease, Age 65–74, Sex (female) xAntithrombotic therapy may be considered in high thromboembolic risk associated with certain cancers (e.g., pancreatic,
ovarian, lung, primary hepatic) or cancer therapies (e.g., cisplatin, gemcitabine, 5-ﬂuorouracil, erythropoietin, granulocyte colony stimulating factors).
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950as electrolyte disturbances that occur frequently in these
patients may also have a proarrhythmic effect. Clinical evi-
dence in this ﬁeld is quite limited. A retrospective analysis
of 81 cancer patients who received ibutilide for cardioversion
of AF or atrial ﬂutter at MD Anderson Cancer Center
showed that the drug was effective in 75% of cases (48). In
the same study, although 84% of patients received at least 1
additional drug associated with QT interval prolongation,
no changes in corrected QT interval were encountered in
any of the patients. Radiofrequency catheter ablation for
pulmonary vein isolation has not yet been studied in cancer
patients, and it may be a good option for some of these
patients, particularly when rhythm control therapy has failed
or there are concerns about its interaction with the back-
ground therapy (49). Nevertheless, there are several issues
that need to be taken into consideration when considering
this technique for cancer patients, such as the high doses of
anticoagulation required during the procedure and the risk
of trauma in cancer patients with a high bleeding risk or the
risk of thromboembolism associated with placing intracar-
diac catheters in those patients with a prothrombotic ten-
dency. Given the lack of evidence of a speciﬁc rhythm- or
rate-control strategy in cancer patients with AF, the strat-
egy followed in other chronic conditions such as heart
failure may be followed, with particular attention to con-
comitant or planned anticancer therapies and comorbid
conditions (50,51).
The management of post-operative AF represents an addi-
tional challenge given its high occurrence rate, especially dur-
ing surgery for lung cancer, as previously stated. Postoperative
N-terminal pro–B-type natriuretic peptide (NT-proBNP)levels may identify patients at increased risk of post-operative
AF and thus guide the use of prophylactic antiarrhythmic
therapy (10). More speciﬁcally, in patients undergoing
thoracic surgery for lung cancer, increased NT-proBNP,
according to the assay’s age-related cutoffs, either 24 h
before or 1 h after surgery, was associated with a sub-
stantially higher rate of AF (64% vs. 5% in patients
without increased NT-proBNP; p < 0.001) (10). Another
study identiﬁed a cutoff post-operative NT-proBNP level
of 182 ng/l for the prediction of post-operative AF (14),
whereas a B-type natriuretic peptide level of 30 pg/ml
had a high speciﬁcity of 93% for predicting AF after
pulmonary resection for lung cancer (52). In addition to
natriuretic peptide level, echocardiographic indexes may
also be useful, particularly those indicating left ventricular
diastolic dysfunction or increased left ventricular diasto-
lic pressures. A mitral E/e0 ratio >8 was highly sensitive
(90% sensitivity) for predicting post-operative AF (16).
Other predictors of post-operative AF include advanced
age, male sex, long duration of surgery, advanced cancer
stage, occurrence of surgical complications, need for post-
operative blood transfusions, and history of hypertension
and pre-operative paroxysmal AF (8,9,11,18).
Several drugs have been studied for the prevention or
management of post-operative AF, mostly in patients un-
dergoing cardiac surgery (Table 3). These agents included
beta-blockers such as metoprolol and landiolol, statins,
angiotensin-converting enzyme inhibitors, omega-3 fatty
acids, and ranolazine (21,53–56). The corresponding data
on cancer patients are limited. Post-operative amiodarone
prophylaxis, given at 300 mg intravenously over 20 min
JACC Vol. 63, No. 10, 2014 Farmakis et al.
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951immediately after surgery followed by 600 mg orally twice
daily for 5 days, reduced the risk of AF by 23% in patients
undergoing lung cancer surgery (12). A cost analysis of this
trial showed that amiodarone was a cost-neutral way to
prevent post-operative AF in lung cancer patients
(57). Furthermore, landiolol, a novel, ultrashort-acting beta-
blocker, when given in a small group of patients who
experienced AF after elective pulmonary resection for lung
cancer, accomplished a more profound perioperative reduc-
tion of heart rate and a quicker restoration of sinus rhythm
compared with historical controls treated with verapamil and
digoxin (13). In another small clinical trial, low-dose human
atrial natriuretic peptide infusion during lung cancer surgery
was protective against post-operative AF in patients with
pre-operative B-type natriuretic peptide increase (30 pg/ml)
(17). In 2 subsequent studies from the same group, human
atrial natriuretic peptide effectively reduced the incidence of
post-operative cardiopulmonary complications during lung
cancer surgery in patients 75 years of age as well as in
patients with chronic obstructive pulmonary disease (58,59).
In contrast, acebutolol induced a nonsigniﬁcant reduction
in the incidence of post-operative AF in patients under-
going pulmonary resection compared with diltiazem or
placebo (60).
Conclusions and Practical Considerations
The accumulated evidence suggests that a large part of AF
in cancer patients results from surgery (4). The presence of
AF may affect patients’ prognosis, whereas its management,
particularly in terms of antithrombotic therapy for stroke
prevention, is a challenge. There are several issues that need
to be addressed by future research concerning epidemiology,
pathogenesis, diagnosis, prevention, and treatment, as out-
lined in Table 4.
Given the lack of evidence, there are currently no speciﬁc
guidelines for AF therapy in patients with malignancies. An
approach to practical issues concerning AF management
based on the current guidelines in noncancer patients (1,61)
and the existing evidence in cancer patients, where availa-
ble, is shown in Table 5. In what concerns antithrom-
botic therapy in particular, certain features like intracranial
tumors, chemotherapy-induced thrombocytopenia, and coa-
gulation defects due to hematological malignancies may
predispose to bleeding and therefore may constitute con-
traindications to antithrombotic therapy, even in patients
at high thromboembolic risk. On the other hand, certain
malignant tumors such as pancreatic, ovarian, lung, and
primary hepatic cancer are associated with an increased
thromboembolic risk, and the same applies to several
chemotherapeutic agents such as cisplatin, gemcitabine, and
5-ﬂuorouracil and supportive therapies like erythropoietin
and granulocyte-colony stimulating factors (62–64). As a
result, antithrombotic prophylaxis may be needed even in
patients classiﬁed as low risk by risk assessment tools such
as CHA2DS2-VASc score or others. An algorithm forantithrombotic therapy in cancer-related AF based on cancer
features and established thromboembolic and bleeding
risk assessment tools (CHA2DS2-VASc and HAS-BLED
[Hypertension, Abnormal renal/liver function, Stroke, Bleed-
ing history or predisposition, Labile international normalized
ratio, Elderly (age >65 years), Drugs/alcohol con-
comitantly], respectively) is proposed in Figure 2. It should
be stressed that the particular clinical features of cancer pa-
tients render an individually tailored therapy even more
crucial, especially for antithrombotic prophylaxis.
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